Novel monoclonal antibody enhances antibody-dependent cellular cytotoxicity in DLBCL, indicating new treatment options.
Key Points
The research aims to evaluate the anti-tumor effects of a novel monoclonal antibody on diffuse large B-cell lymphoma cells, focusing on the mechanisms involved in antibody-dependent cellular cytotoxicity.
Used CD16-expressing NK92 cells against DLBCL cell lines in co-culture assays.
Developed a high-content, high-throughput screening tool to evaluate FDA approved drugs.
Analyzed the effects of BCR-Abl inhibitors on antibody-mediated cytotoxicity.
Antibody X predominantly functions through antibody-dependent cellular cytotoxicity (ADCC) rather than direct cytotoxicity.
ADCC is regulated by Src kinases and requires LFA-1/ICAM-1 interaction between immune effector cells and lymphoma cells.
The developed ADCC platform can facilitate combinatorial drug screening and mechanistic evaluations.